Coya gets $3.85M from Dr. Reddy's for COYA 302 Phase 2 trial; first $6M royalties waived

Coya Therapeutics, Inc.

Dr. Reddy's makes $3.85M one-time payment to Coya for funding first Phase 2 trial of COYA 302 in ALS.
Dr. Reddy's has no obligation to pay the first $6M in royalties otherwise due under the DRL Development Agreement.
Amendment effective June 4, 2024; payment due within 5 business days of Coya's invoice.
Funds must be used solely for the Phase 2 trial in the U.S. as per the Development Plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.